Q-omics provides the consensus-scored ZNF426 profile across patient tissues and cancer cell-line models. ZNF426 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF426 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ZNF426 RNA expression shows 20,664 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, THCA, and KIRP as cancer lineages where ZNF426 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF426 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF426 survival associations across molecular data types. ZNF426 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF426 RNA expression–survival associations across cancer types. High ZNF426 expression shows unfavorable associations in LGG, but favorable associations in KIRC, HNSC, OV, SCLC and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF426 RNA expression.
This table summarizes ZNF426 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF426. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF426 shows lower tumor expression in THCA, KIRC, BRCA and LUAD and higher tumor expression in LIHC and CHOL. The THCA box plot shows higher ZNF426 RNA expression in normal versus tumor tissue (log2 FC = −0.462, t-test p < 0.001).
This table shows molecular features associated with ZNF426 in patient tissues and cancer cell lines. In patient samples, ZNF426 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF426 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
